百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性三阴乳腺癌III期临试期中分析达到主要终点

Core Viewpoint - The announcement from Baillie Gifford (688506.SH) indicates that the mid-term analysis of the Phase III clinical trial for iza-bren (EGFR×HER3 bispecific ADC) has met its primary endpoints, suggesting early regulatory submission while continuing patient follow-up [1] Group 1: Clinical Trial Results - The independent data monitoring committee (iDMC) recommended early regulatory communication based on the current analysis results [1] - Topline data shows that iza-bren significantly extends progression-free survival (PFS) and overall survival (OS), achieving dual primary endpoints [1] - This Phase III clinical trial is the third to achieve primary endpoints for this bispecific ADC and is the first globally to report positive PFS/OS results in triple-negative breast cancer treatment [1]